These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33169789)

  • 21. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response.
    Wu Y; Zhai W; Zhou X; Wang Z; Lin Y; Ran L; Qi Y; Gao Y
    J Immunol Res; 2018; 2018():2942679. PubMed ID: 30596107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine.
    Batchu RB; Gruzdyn O; Potti RB; Weaver DW; Gruber SA
    JAMA Surg; 2014 May; 149(5):451-7. PubMed ID: 24671426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the cancer-testis antigen BORIS to design a novel multi-epitope vaccine against breast cancer based on immunoinformatics approaches.
    Mahdevar E; Safavi A; Abiri A; Kefayat A; Hejazi SH; Miresmaeili SM; Iranpur Mobarakeh V
    J Biomol Struct Dyn; 2022 Sep; 40(14):6363-6380. PubMed ID: 33599191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-based approaches to develop epitope-driven subunit vaccines against pathogens of infective endocarditis.
    Priyadarshini V; Pradhan D; Munikumar M; Swargam S; Umamaheswari A; Rajasekhar D
    J Biomol Struct Dyn; 2014; 32(6):876-89. PubMed ID: 24404767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metadherin peptides containing CD4(+) and CD8(+) T cell epitopes as a therapeutic vaccine candidate against cancer.
    Dhiman G; Lohia N; Jain S; Baranwal M
    Microbiol Immunol; 2016 Sep; 60(9):646-52. PubMed ID: 27554419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis and designing of peptide vaccine using PE-PGRS family protein of Mycobacterium ulcerans-An integrated vaccinomics approach.
    Nain Z; Karim MM; Sen MK; Adhikari UK
    Mol Immunol; 2020 Apr; 120():146-163. PubMed ID: 32126449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prediction synthesis and identification of HLA-A2-restricted cytotoxic T lymphocyte epitopes of the tumor antigen MAGE-n].
    Dong HL; Sui YF; Ye J; Li ZS; Qu P; Zhang XM; Chen GS; Lu SY
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(12):1080-3. PubMed ID: 12899783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide-Binding Groove Contraction Linked to the Lack of T Cell Response: Using Complex Structure and Energy To Identify Neoantigens.
    Pang YP; Elsbernd LR; Block MS; Markovic SN
    Immunohorizons; 2018 Aug; 2(7):216-225. PubMed ID: 31022692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses.
    Sartorius R; Pisu P; D'Apice L; Pizzella L; Romano C; Cortese G; Giorgini A; Santoni A; Velotti F; De Berardinis P
    J Immunol; 2008 Mar; 180(6):3719-28. PubMed ID: 18322177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoinformatics Approach to Design Novel Subunit Vaccine against the Epstein-Barr Virus.
    Moin AT; Patil RB; Tabassum T; Araf Y; Ullah MA; Snigdha HJ; Alam T; Alvey SA; Rudra B; Mina SA; Akter Y; Zhai J; Zheng C
    Microbiol Spectr; 2022 Oct; 10(5):e0115122. PubMed ID: 36094198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of multi-epitope, analogue-based cancer vaccines.
    Fikes JD; Sette A
    Expert Opin Biol Ther; 2003 Sep; 3(6):985-93. PubMed ID: 12943457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen.
    Zhu B; Chen Z; Cheng X; Lin Z; Guo J; Jia Z; Zou L; Wang Z; Hu Y; Wang D; Wu Y
    Clin Cancer Res; 2003 May; 9(5):1850-7. PubMed ID: 12738743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
    Dutoit V; Taub RN; Papadopoulos KP; Talbot S; Keohan ML; Brehm M; Gnjatic S; Harris PE; Bisikirska B; Guillaume P; Cerottini JC; Hesdorffer CS; Old LJ; Valmori D
    J Clin Invest; 2002 Dec; 110(12):1813-22. PubMed ID: 12488431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards patient-specific tumor antigen selection for vaccination.
    Rammensee HG; Weinschenk T; Gouttefangeas C; Stevanović S
    Immunol Rev; 2002 Oct; 188():164-76. PubMed ID: 12445290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.